Hi Mark,
We haven’t come across VFY before, the $250mn biotech which listed in late 2024, but we’re always keen to look at new stocks, particularly when we see a stock perform so strongly. For subscribers not familiar with VFY, its a healthcare technology company developing cryopreservation hardware and software that improves the storage and transport of biological materials, serving markets including cell and gene therapy, blood products and animal reproduction.
- VFY has surged ~150% YTD in 2026, driven entirely by a series of company-specific commercial partnerships and clinical validation milestones.
The stocks rally reflects a rapid accumulation of US institutional partnerships, military, blood banking, and agricultural, that have validated its Guardion device technology and opened a potentially large addressable market around the 2027 discontinuation of legacy red blood cell cryopreservation systems. The broader biotech funding environment has also been supportive, with global biotech venture funding on track to exceed the 2021 peak of USD$26.7bn.
- VFY raised $30 million in June at $2.60 per share. While the company did not disclose a formal bookbuild multiple, pricing at the top of its $25–30 million target range in a non-underwritten raising suggests strong demand.
We don’t now VFY at all well, so our comments should be considered with that in mind, but technically it looks good and a test of $4 looks likely in 2026/7.